martes, 6 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 16, 2026

Hedge Fund Delta Global Exited Its Stake in Abercrombie & Fitch Stock. Here's What That Means for Investors.

View original at finance.yahoo.com
Hedge Fund Delta Global Exited Its Stake in Abercrombie & Fitch Stock. Here's What That Means for Investors. What happened According to an SEC filing dated May 15, 2026, Delta Global Management LP sold its entire holding of 203,145 shares in Abercrombie & Fitch Co.(NYSE:ANF) during the first quarter…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Delta Global Management reported 153 equity positions at quarter-end with $1.22 billion in reportable U.S. equity assets.

    60% confidence
  • Delta Global Management's disposition of ANF makes sense given shares hit a 52-week high of $133.11 in January.

    60% confidence
  • The quarter-end value of Delta Global's ANF position declined by $25.57 million, reflecting both the share sale and stock price changes.

    60% confidence
  • Delta Global Management LP sold its entire holding of 203,145 shares in Abercrombie & Fitch Co. during Q1 2026 with an estimated transaction value of $19.75 million.

    60% confidence
  • Abercrombie & Fitch operates a specialty retail business model focused on direct-to-consumer sales through both physical stores and digital platforms.

    60% confidence

Data points we hold from this source

Citigroup Inc. · market share58.06 USD
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com